Cue Biopharma to Present at the Guggenheim I&I Spotlight Series
BOSTON, July 11, 2022 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class...
News
Athenex Announces Entry into Agreement to Sell its China API Business to TiHe Capital (Bejing) Co., Ltd.
Expected sale proceeds of approximately $19.0 millionCompany continues to monetize non-core assets to extend cash runwayProceeds from the deal will...
SAB Biotherapeutics Announces Election of Rear Admiral (retired) Scott Giberson, RPh, MPH, D.Sc., to Board of Directors
SIOUX FALLS, S.D., July 11, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), (SAB), a clinical-stage biopharmaceutical company with a...
Healthcare Triangle Announces $6.5 Million Private Placement
PLEASANTON, Calif., July 11, 2022 (GLOBE NEWSWIRE) -- Healthcare Triangle Inc., (Nasdaq: HCTI) (“HCTI” or the “Company”), a leading provider...
US FDA Grants Spectral Medical Breakthrough Device Designation for Toraymyxin™ (“PMX”) for the Treatment of Endotoxemic Septic Shock
Breakthrough designation expected to help accelerate regulatory reviewTORONTO, July 11, 2022 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the...
EyePoint Pharmaceuticals to Host Investor Day on July 18, 2022
- Guest speakers Carl Regillo, M.D., FACS, Professor of Ophthalmology, Thomas Jefferson University and Charles C. Wykoff, M.D., Ph.D., Director...
Iterum Therapeutics Announces Special Protocol Assessment (SPA) Agreement With the FDA
--SPA supports protocol for Phase 3 Clinical Trial of Oral Sulopenem for the treatment of Uncomplicated Urinary Tract Infections-- --Clinical...
Opus Genetics to Present at OIS Retina Innovation Summit 2022
RESEARCH TRIANGLE PARK, N.C., July 11, 2022 (GLOBE NEWSWIRE) -- Opus Genetics, a patient-first gene therapy company developing treatments for...
Jushi Announces Grand Reopening of Beyond Hello™ Palm Springs
Jushi Holdings Inc. Announces Grand Reopening of Palm Springs Dispensary Jushi Holdings Inc. to host the grand reopening of its...
Quipt Surpasses 200,000 Active Patients Adding Approximately $7 Million in Annualized Revenues, and Anticipated $1.4 Million of Adjusted EBITDA Post Integration
Acquisition of Hometown Medical, LLC Significantly Enhances Presence in MississippiCINCINNATI, July 11, 2022 (GLOBE NEWSWIRE) -- Quipt Home Medical Corp....
Atea Pharmaceuticals Participates in the William Blair Biotech Focus Conference
BOSTON, July 11, 2022 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that...
Axogen, Inc. Appoints William Burke to Board of Directors
Burke brings 25+ years of global financial leadership experience to the Axogen, Inc. Board of DirectorsALACHUA, Fla. and TAMPA, Fla.,...
EyePoint Pharmaceuticals Appoints Karen Zaderej to Board of Directors
WATERTOWN, Mass., July 11, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and...
MediWound Announces Positive Initial Data from its U.S. Phase I/II Study of MW005 for the Treatment of Basal Cell Carcinoma
MW005 Shown to Be Safe and Well-ToleratedTarget Lesions Clearance Data Provides Clinical Efficacy Proof-of-Concept YAVNE, Israel, July 11, 2022 (GLOBE...
TScan Therapeutics Announces Publication in Cell Highlighting the Discovery of Tumor Antigens and TCRs for the Treatment of Solid Tumors Using Foundational Screening Technology
TScan screening technology used to identify the targets of expanded T cell clones in the tumors of patients with head...
Tonix Pharmaceuticals Announces Development of TNX-601 ER, a Potential Abuse Deterrent, Extended-Release Formulation of Tianeptine Oxalate for the Treatment of Major Depressive Disorder
Naloxone-Free Formulation of Tianeptine is an Extended-Release Tablet that Includes Inactive Ingredients and Compression Properties Designed to Confer Abuse Deterrence...
Algernon Pharmaceuticals Provides Update on its Planned Phase 1 Repirinast Chronic Kidney Disease Study
VANCOUVER, British Columbia, July 11, 2022 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB:...
Immunocore announces dosing of first patient with ImmTAV® bispecific for HIV
PRESS RELEASE Immunocore announces dosing of first patient with ImmTAV® bispecific for HIV IMC-M113V, T cell receptor bispecific, targets an...
Allarity Therapeutics Bolsters Its Board of Directors with Appointment of Prominent Clinical Researcher and Oncology Drug Developer, David A. Roth, M.D.
Interim CEO James G. Cullem, J.D. and Co-Founder Thomas Jensen also joining the Board Press ReleaseCambridge, MA, U.S.A. (July...
EMERALD HEALTH SCIENCES INC.
EARLY WARNING NEWS RELEASE Vancouver, British Columbia, July 11, 2022 (GLOBE NEWSWIRE) -- Emerald Health Sciences Inc. ("Sciences") announces that...